Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2016, Article ID 6084270, 4 pages
http://dx.doi.org/10.1155/2016/6084270
Clinical Study

Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes

Ophthalmology Department, Mohammed VI University Hospital, 40000 Marrakech, Morocco

Received 22 February 2016; Accepted 25 July 2016

Academic Editor: Jesús Pintor

Copyright © 2016 Belghmaidi Sarah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Benyaddoun, G. Casse, R. Forte, B. Dallaudière, J. P. Adenis, and P. Y. Robert, “Néovascularisation cornéenne: aspects épidémiologiques, physiopathologiques et cliniques,” Journal Français d'Ophtalmologie, vol. 36, no. 7, pp. 627–639, 2013. View at Publisher · View at Google Scholar
  2. C. T. Pillai, H. S. Dua, and P. Hossain, “Fine needle diathermy occlusion of corneal vessels,” Investigative Ophthalmology and Visual Science, vol. 41, no. 8, pp. 2148–2153, 2000. View at Google Scholar · View at Scopus
  3. R. C. Ey, W. F. Hughes, M. A. Bloome et al., “Prevention of cornealvascularization,” American Journal of Ophthalmology, vol. 66, no. 6, pp. 1118–1131, 1968. View at Publisher · View at Google Scholar
  4. W. Stevenson, S.-F. Cheng, M. H. Dastjerdi, G. Ferrari, and R. Dana, “Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) Vs bevacizumab (Avastin),” Ocular Surface, vol. 10, no. 2, pp. 67–83, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-H. Chang, E. E. Gabison, T. Kato, and D. T. Azar, “Corneal neovascularization,” Current Opinion in Ophthalmology, vol. 12, no. 4, pp. 242–249, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. G. K. Klintworth, Corneal Angiogenesis: A Comprehensive Critical Review, Springer, New York, NY, USA, 1991.
  7. D. Gupta and C. Illingworth, “Treatments for corneal neovascularization: a review,” Cornea, vol. 30, no. 8, pp. 927–938, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. A. Jørgensen and E. Stoffersen, “Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin production,” Pharmacological Research Communications, vol. 13, no. 6, pp. 579–586, 1981. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Frucht and H. Zauberman, “Topical indomethacin effect on neovascularisation of the cornea and on prostaglandin E2 levels,” British Journal of Ophthalmology, vol. 68, no. 9, pp. 656–659, 1984. View at Publisher · View at Google Scholar · View at Scopus
  10. V. H. Pai and S. V. B. Handary, “Necrotizing scleritis following laser therapy for corneal vascularization,” Annals of Ophthalmology, vol. 41, no. 1, pp. 50–51, 2009. View at Google Scholar · View at Scopus
  11. A. Solomon, P. Ellies, D. F. Anderson et al., “Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency,” Ophthalmology, vol. 109, no. 6, pp. 1159–1166, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. A. C. C. Vieira, A. L. Höfling-Lima, J. Á. P. Gomes, D. De Freitas, M. E. Farah, and R. Belfort, “Intrastromal injection of bevacizumab in patients with corneal neovascularization,” Arquivos Brasileiros de Oftalmologia, vol. 75, no. 4, pp. 277–279, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. N. Hashemian, M. A. Zare, F. Rahimi, and M. Mohammadpour, “Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique,” Cornea, vol. 30, no. 2, pp. 215–218, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Ferrara, K. J. Hillan, H.-P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 391–400, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Mohammadpour, “Deep intrastromal injection of bevacizumab for the management of corneal neovascularization,” Cornea, vol. 32, no. 1, pp. 109–110, 2013. View at Publisher · View at Google Scholar
  16. S. N. Yeung, A. Lichtinger, P. Kim, M. D. Amiran, and A. R. Slomovic, “Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization,” Cornea, vol. 30, no. 10, pp. 1110–1114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Maddula, D. K. Davis, S. Maddula, M. K. Burrow, and B. K. Ambati, “Horizons in therapy for corneal angiogenesis,” Ophthalmology, vol. 118, no. 3, pp. 591–599, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Gueudry, F. Richez, B. Tougeron-Brousseau, O. Genevois, and M. Muraine, “Injections sous-conjonctivales de bévacizumab dans le traitement de la néovascularisation cornéenne,” Journal Français d'Ophtalmologie, vol. 33, no. 9, pp. 630–636, 2010. View at Publisher · View at Google Scholar
  19. F. Bock, Y. König, F. Kruse, M. Baier, and C. Cursiefen, “Bevacizumab (Avastin) eye drops inhibit corneal neovascularization,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 2, pp. 281–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Awadein, “Subconjunctival bevacizumab for vascularized rejected corneal grafts,” Journal of Cataract and Refractive Surgery, vol. 33, no. 11, pp. 1991–1993, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. H. Dastjerdi, K. M. Al-Arfaj, N. Nallasamy et al., “Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study,” Archives of Ophthalmology, vol. 127, no. 4, pp. 381–389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Y. Oh, M. K. Kim, M. S. Shin, H. J. Lee, J. H. Lee, and W. R. Wee, “The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas,” Current Eye Research, vol. 34, no. 2, pp. 85–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. J. Ahn, H. B. Hwang, and S. K. Chung, “Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment,” Korean Journal of Ophthalmology, vol. 28, no. 2, pp. 177–180, 2014. View at Publisher · View at Google Scholar · View at Scopus